Skip to main content
Clinical Trials/ISRCTN78768849
ISRCTN78768849
Completed
Not Applicable

A single centre randomised clinical trial to assess the antibody response to a 23-valent pneumococcal polysaccharide vaccine administered to adults aged between 50 - 70 years following a 0, 1 or 2 dose priming immunisation with a 7-valent pneumococcal conjugate vaccine

niversity of Oxford (UK)0 sites348 target enrollmentJuly 28, 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Oxford (UK)
Enrollment
348
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 28, 2006
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Oxford (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy adults aged 50 \- 70 years inclusive
  • 2\. In good health as determined by:
  • 2\.1\. Medical history
  • 2\.2\. History\-directed physical examination
  • 2\.3\. Clinical judgment of the investigator
  • 3\. Able (in the Investigators opinion) and willing to comply with all study requirements including be available for all the visits scheduled in the study
  • 4\. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria

  • 1\. Have previously received any pneumococcal vaccine
  • 2\. Have received vaccination with a vaccine containing either CRM197 or Diphtheria toxoid within the past 12 months
  • 3\. Have a previous ascertained or suspected disease caused C. diphtheriae, or Pneumococcus
  • 4\. Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component
  • 5\. Have a known or suspected autoimmune disease or impairment /alteration of immune function resulting from (for example):
  • 5\.1\. Receipt of any immunosuppressive therapy
  • 5\.2\. Receipt of immunostimulants
  • 5\.3\. Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti\-cancer chemotherapy or radiation therapy within the preceding 6 months or long\-term systemic corticosteroid therapy\* (\*prednisolone or equivalent for more than two consecutive weeks within the past 3 months)
  • 6\. Have a suspected or known human immunodeficiency virus (HIV) infection or HIV related disease
  • 7\. Have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months

Outcomes

Primary Outcomes

Not specified

Similar Trials